Review of bimekizumab in the treatment of psoriasis

References

• Korman NJ. Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol. 2020 Apr;182(4):1–8. doi:10.1111/bjd.18245. PMID: 31225638.
   PubMed Web of Science ®Google Scholar
• Singh R, Koppu S, Perche PO, Feldman SR. The cytokine mediated molecular pathophysiology of psoriasis and its clinical implications. Int J Mol Sci. 2021 Nov 26;22(23):12793. doi:10.3390/ijms222312793. PMID: 34884596.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020 May 19;323(19):1945–1960. doi:10.1001/jama.2020.4006. PMID: 32427307.
   PubMed Web of Science ®Google Scholar
• Bellinato F, Gisondi P, Girolomoni G. Latest advances for the treatment of chronic plaque psoriasis with biologics and oral small molecules. Biologics. 2021 June 29;15:247–253. doi:10.2147/BTT.S290309. PMID: 34239295.
   PubMed Web of Science ®Google Scholar
• Raharja A, Mahil SK, Barker JN. Psoriasis: a brief overview. Clin Med (Lond). 2021 May;21(3):170–173. doi:10.7861/clinmed.2021-0257. PMID: 34001566.
   PubMed Web of Science ®Google Scholar
• Monks G, Rivera-Oyola R, Lebwohl M. The psoriasis decision tree. J Clin Aesthet Dermatol. 2021 Apr;14(4):14–22. PMID: 34055182.
   PubMedGoogle Scholar
• Ocampo DV, Gladman D. Psoriatic arthritis. F1000res. 2019 Sept 20;8: F1000 Faculty Rev-1665. PMID: 31583079. doi:10.12688/f1000research.19144.1.
   PubMedGoogle Scholar
• Hawkes JE, Yan BY, Chan TC, Krueger JG. Discovery of the IL-23/IL-17 signaling pathway and the treatment of psoriasis. J Immunol. 2018 Sept 15;201(6):1605–1613. doi:10.4049/jimmunol.1800013. PMID: 30181299.
   PubMed Web of Science ®Google Scholar
• Adams R, Maroof A, Baker T, Lawson ADG, Oliver R, Paveley R, Rapecki S, Shaw S, Vajjah P, West S, et al. Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F. Front Immunol. 2020 Aug 21;11:1894. doi:10.3389/fimmu.2020.01894. PMID: 32973785.
   PubMed Web of Science ®Google Scholar
• Reid C, Griffiths CEM. Psoriasis and treatment: past, present and future aspects. Acta Derm Venereol. 2020 Jan 30;100(3):adv00032. doi:10.2340/00015555-3386. PMID: 31971601.
   PubMed Web of Science ®Google Scholar
• Papp KA, Merola JF, Gottlieb AB, Griffiths CEM, Cross N, Peterson L, Cioffi C, Blauvelt A. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. J Am Acad Dermatol. 2018 Aug;79(2):277–286.e10. doi:10.1016/j.jaad.2018.03.037. PMID: 29609013.
   PubMed Web of Science ®Google Scholar
• Reich K, Papp KA, Blauvelt A, Langley RG, Armstrong A, Warren RB, Gordon KB, Merola JF, Okubo Y, Madden C, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet. 2021 Feb 6;397(10273):487–498. doi:10.1016/S0140-6736(21)00125-2. PMID: 33549193.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Foley P, Krueger JG, Pinter A, Reich K, Vender R, Vanvoorden V, Madden C, White K, Cioffi C, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet. 2021 Feb 6;397(10273):475–486. doi:10.1016/S0140-6736(21)00126-4. PMID: 33549192.
   PubMed Web of Science ®Google Scholar
• Warren RB, Blauvelt A, Bagel J, Papp KA, Yamauchi P, Armstrong A, Langley RG, Vanvoorden V, De Cuyper D, Cioffi C, et al. Bimekizumab versus Adalimumab in plaque psoriasis. N Engl J Med. 2021 July 8;385(2):130–141. doi:10.1056/NEJMoa2102388. PMID: 33891379.
   PubMed Web of Science ®Google Scholar
• Reich K, Warren RB, Lebwohl M, Gooderham M, Strober B, Langley RG, Paul C, De Cuyper D, Vanvoorden V, Madden C, et al. Bimekizumab versus Secukinumab in plaque psoriasis. N Engl J Med. 2021 July 8;385(2):142–152. doi:10.1056/NEJMoa2102383. PMID: 33891380.
   PubMed Web of Science ®Google Scholar
• Godeau D, Petit A, Richard I, Roquelaure Y, Descatha A. Return-to-work, disabilities and occupational health in the age of COVID-19. Scand J Work Environ Health. 2021 July 1;47(5):408–409. doi:10.5271/sjweh.3960. PMID: 34003294.
   PubMed Web of Science ®Google Scholar
• Bakar RS, Jaapar SZS, Azmi AF, Aun YC. Depression and anxiety among patients with psoriasis: a correlation with quality of life and associated factors. J Taibah Univ Med Sci. 2021 Mar 16;16(4):491–496. doi:10.1016/j.jtumed.2021.02.008. PMID: 34408605.
   PubMed Web of Science ®Google Scholar
• Freitas E, et al. Bimekizumab for the treatment of psoriasis. Drugs. 2021 Oct;81(15):1751–1762. doi:10.1007/s40265-021-01612-z. PMID: 34623614.
   PubMed Web of Science ®Google Scholar
• Freitas E, Torres T. Bimekizumab: the new drug in the biologics armamentarium for psoriasis. Drugs Context. 2021 June 8;10:2021-4–1. doi:10.7573/dic.2021-4-1. PMID: 34178093.
   Google Scholar
• Reis J, Vender R, Torres T. Bimekizumab: the first dual inhibitor of interleukin (IL)-17A and IL-17F for the treatment of psoriatic disease and Ankylosing Spondylitis. BioDrugs. 2019 Aug;33(4):391–399. doi:10.1007/s40259-019-00361-6. PMID: 31172372.
   PubMed Web of Science ®Google Scholar
• Glatt S, Helmer E, Haier B, Strimenopoulou F, Price G, Vajjah P, Harari OA, Lambert J, Shaw S. First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis. Br J Clin Pharmacol. 2017 May;83(5):991–1001. doi:10.1111/bcp.13185. PMID: 27859546.
   PubMed Web of Science ®Google Scholar
• Bai F, Li GG, Liu Q, Niu X, Li R, Ma H. Short-term efficacy and safety of IL-17, IL-12/23, and IL-23 inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the treatment of moderate to severe plaque psoriasis: a systematic review and network meta-analysis of randomized controlled trials. J Immunol Res. 2019 Sept 10;2019:2546161. doi:10.1155/2019/2546161. PMID: 31583255.
   PubMed Web of Science ®Google Scholar
• Sbidian E, Chaimani A, Garcia-Doval I, Doney L, Dressler C, Hua C, Hughes C, Naldi L, Afach S, Le Cleach L. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2022 May 23;5(5):CD011535.doi:10.1002/14651858.CD011535.pub5. PMID: 35603936; PMCID: PMC9125768.24.
   PubMedGoogle Scholar
• Huppler AR, Bishu S, Gaffen SL. Mucocutaneous candidiasis: the IL-17 pathway and implications for targeted immunotherapy. Arthritis Res Ther. 2012 July 23;14(4):217. doi:10.1186/ar3893. PMID: 22838497.
   PubMed Web of Science ®Google Scholar